Evidence map›Paper›PMID 36672720›Full record

ArticleBiomedicines2023

Longitudinal Measurement of Histidine-Rich Glycoprotein Levels in Bronchopulmonary Dysplasia: A Pilot Study.

Daisaku Morimoto, Yosuke Washio, Kei Tamai, Takeshi Sato, Tomoka Okamura, Hirokazu Watanabe, Yu Fukushima, Junko Yoshimoto, Misao Kageyama, Kenji Baba and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Daisaku MorimotoDepartment of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho Kita-ku, Okayama 700-8558, Japan.ORCID 0000-0002-1035-3526
Yosuke WashioDepartment of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho Kita-ku, Okayama 700-8558, Japan.ORCID 0000-0003-3601-3420
Kei TamaiDivision of Neonatology, Okayama Medical Center, National Hospital Organization, Okayama, 1711-1 Tamasu Kita-ku, Okayama 701-1192, Japan.ORCID 0000-0002-3343-1590
Takeshi SatoDepartment of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho Kita-ku, Okayama 700-8558, Japan.
Tomoka OkamuraDepartment of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho Kita-ku, Okayama 700-8558, Japan.
Hirokazu WatanabeDepartment of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho Kita-ku, Okayama 700-8558, Japan.
Yu FukushimaDivision of Neonatology, Okayama Medical Center, National Hospital Organization, Okayama, 1711-1 Tamasu Kita-ku, Okayama 701-1192, Japan.
Junko YoshimotoDepartment of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho Kita-ku, Okayama 700-8558, Japan.
Misao KageyamaDivision of Neonatology, Okayama Medical Center, National Hospital Organization, Okayama, 1711-1 Tamasu Kita-ku, Okayama 701-1192, Japan.
Kenji BabaDepartment of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho Kita-ku, Okayama 700-8558, Japan.ORCID 0000-0002-2716-5185
Hirokazu TsukaharaDepartment of Pediatrics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikatacho Kita-ku, Okayama 700-8558, Japan.
Okayama University · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histidine-rich glycoprotein (HRG) has been reported to inhibit signaling leading to the release of high mobility group box 1 protein, a damage-associated molecular pattern. The present study aimed to determine the longitudinal change in HRG levels in extremely preterm infants and assess whether complications such as bronchopulmonary dysplasia (BPD) were associated with differences in HRG levels. In this multicenter, prospective, observational study, we measured serum HRG levels every 2 weeks from birth to 8 weeks of age. Serum HRG was measured using an enzyme-linked immunosorbent assay. We included 19 extremely preterm infants in the study and 74 samples were analyzed. The median gestational age was 26.0 weeks, and the median birth weight was 858 g. Serum HRG levels showed a significant upward trend after birth (p < 0.001); median HRG concentrations at birth and at 2, 4, 6, and 8 weeks of age were 1.07, 1.11, 2.86, 6.05, and 7.49 µg/mL, respectively. Onset of BPD was not associated with differences in serum HRG levels. Further, the serum HRG levels increased significantly after birth in extremely preterm infants.

Indexed as

bronchopulmonary dysplasiaextremely preterm infantshigh mobility group box 1histidine-rich glycoproteinlongitudinal measurementmixed-effects model

Identifiers

PMID36672720
PMCPMC9855564
OpenAlexW4316465516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.